NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News

$2.20

+0.17 (+8.37%)

(As of 02:52 PM ET)

Compare

Today's Range: $2.00
▼
$2.29
50-Day Range: $0.80
▼
$2.20
52-Week Range: $0.65
▼
$2.41

Volume: 3.30 million shs
Average Volume: 2.16 million shs
Market Capitalization: $268.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 59.1% Upside
$3.50 Price Target
Short Interest: Healthy
2.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.25
Based on 2 Articles This Week
Insider Trading: Selling Shares
$12,269 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.63) to ($0.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

263rd out of 1,980 stocks

Biological Products, Except Diagnostic Industry

39th out of 330 stocks

3.5

Analyst's Opinion

Consensus Rating
X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, X4 Pharmaceuticals has a forecasted upside of 59.1% from its current price of $2.20.
Amount of Analyst Coverage
X4 Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.41% of the outstanding shares of X4 Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
X4 Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in X4 Pharmaceuticals has recently decreased by 2.64%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
X4 Pharmaceuticals does not currently pay a dividend.
Dividend Growth
X4 Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
X4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for X4 Pharmaceuticals is -0.85.

2.4

News and Social Media Coverage

News Sentiment
X4 Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
44 people have searched for XFOR on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.
MarketBeat Follows
7 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,269.00 in company stock.
Percentage Held by Insiders
Only 1.08% of the stock of X4 Pharmaceuticals is held by insiders.
Percentage Held by Institutions
56.46% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of X4 Pharmaceuticals is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of X4 Pharmaceuticals is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
X4 Pharmaceuticals has a P/B Ratio of 5.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

May 25, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)

May 24, 2023 | americanbankingnews.com

FY2023 EPS Estimates for X4 Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:XFOR)

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.

May 23, 2023 | americanbankingnews.com

B. Riley Analysts Raise Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

May 20, 2023 | americanbankingnews.com

Stifel Nicolaus Boosts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $5.00

May 20, 2023 | americanbankingnews.com

FY2026 EPS Estimates for X4 Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:XFOR)

May 19, 2023 | americanbankingnews.com

Brookline Capital Management Analysts Raise Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

May 17, 2023 | msn.com

Stifel Maintains X4 Pharmaceuticals (XFOR) Buy Recommendation

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

May 17, 2023 | msn.com

Unusual Call Option Trade in X4 Pharmaceuticals (XFOR) Worth $24.36K

May 17, 2023 | msn.com

X4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of Infections

May 16, 2023 | finance.yahoo.com

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

May 16, 2023 | finance.yahoo.com

X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market

May 10, 2023 | americanbankingnews.com

Analysts Set Expectations for X4 Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:XFOR)

May 6, 2023 | americanbankingnews.com

Opthea (NASDAQ:OPT) versus X4 Pharmaceuticals (NASDAQ:XFOR) Critical Contrast

May 5, 2023 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About X4 Pharmaceuticals

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates X4 Pharmaceuticals (XFOR) Buy Recommendation

May 4, 2023 | msn.com

X4 Pharmaceuticals: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

April 29, 2023 | americanbankingnews.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 86.8% in April

April 26, 2023 | finance.yahoo.com

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

April 26, 2023 | finance.yahoo.com

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32%

April 12, 2023 | finance.yahoo.com

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)

April 12, 2023 | americanbankingnews.com

X4 Pharmaceuticals (NASDAQ:XFOR) Given New $3.00 Price Target at B. Riley

April 10, 2023 | msn.com

B. Riley Securities Maintains X4 Pharmaceuticals (XFOR) Buy Recommendation

April 6, 2023 | markets.businessinsider.com

B.Riley Financial Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)

April 4, 2023 | finance.yahoo.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

XFOR Price History

30 days | 90 days | 365 days | Advanced Chart

XFOR Company Calendar

Last Earnings: 3/21/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XFOR
CUSIP: N/A
CIK: 1501697
Web: www.x4pharma.com
Phone: (857) 529-8300
Fax: N/A
Employees: 83
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.50
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +72.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,870,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -176.29%
Return on Assets: -80.88%

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 5.04
Quick Ratio: 5.04

Sales & Book Value

Annual Sales: $3 million
Price / Sales: 82.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.42 per share
Price / Book: 4.83

Miscellaneous

Outstanding Shares: 122,210,000
Free Float: 120,887,000
Market Cap: $248.09 million
Optionable: Not Optionable
Beta: 0.70

Key Executives

Paula S. Ragan
President, Chief Executive Officer & Director

Mary DiBiase
Chief Operating Officer

Adam S. Mostafa
Chief Financial Officer & Treasurer

Murray Willis Stewart
Independent Director & Chief Medical Officer

Art Taveras
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings or view top-rated stocks.
What is X4 Pharmaceuticals' stock price forecast for 2023?: 5 brokerages have issued 1 year price targets for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 72.4% from the stock's current price.
View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts.
How have XFOR shares performed in 2023?: X4 Pharmaceuticals' stock was trading at $0.9930 at the start of the year. Since then, XFOR shares have increased by 104.4% and is now trading at $2.03.
View the best growth stocks for 2023 here.
When is X4 Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XFOR earnings forecast.
How were X4 Pharmaceuticals' earnings last quarter?: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06.
What ETFs hold X4 Pharmaceuticals' stock?: ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and Simplify Propel Opportunities ETF (SURI) and

What other stocks do shareholders of X4 Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).
What is X4 Pharmaceuticals' stock symbol?: X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."
Who are X4 Pharmaceuticals' major shareholders?: X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (3.72%), AXA S.A. (3.60%), Geode Capital Management LLC (0.91%), Schonfeld Strategic Advisors LLC (0.85%), Ghost Tree Capital LLC (0.70%) and JPMorgan Chase & Co. (0.51%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mary Dibiase, Paula Ragan and Renato Skerlj.
View institutional ownership trends.
How do I buy shares of X4 Pharmaceuticals?: Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is X4 Pharmaceuticals' stock price today?: One share of XFOR stock can currently be purchased for approximately $2.03.
How much money does X4 Pharmaceuticals make?: X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $248.09 million and generates $3 million in revenue each year. The company earns $-93,870,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.
How can I contact X4 Pharmaceuticals?: X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News

X4 Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

XFOR Stock News Headlines

XFOR Price History

XFOR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

XFOR Stock - Frequently Asked Questions

Overall MarketRank^™